inosine; 58-63-9; Hypoxanthosine; Ribonosine; Atorel; Oxiamin; Hypoxanthine riboside; Trophicardyl; Selfer; Pantholic-L; Panholic-L; beta-Inosine; Hypoxanthine D-riboside; (-)-Inosine; Hypoxanthine ribonucleoside; 9-beta-D-Ribofuranosylhypoxanthine; Hypoxanthine nucleoside; INO 495; Inosina; Inosinum; Inosie; iso-prinosine; Inosine [INN:JAN]; Inosinum [INN-Latin]; Inosina [INN-Spanish]; hypoxanthine-ribose; NSC 20262; Hypoxanthine, 9-beta-D-ribofuranosyl-; Inosin; Inotin; AI3-52241; Hypoxanthine 9-beta-D-ribofuranoside; INO; beta-D-Ribofuranoside, hypoxanthine-9; HXR; Hypoxanthine-9-beta-D-ribofuranoside; MLS000028518; DTXSID2045993; CHEBI:17596; 5A614L51CT; 9.beta.-D-Ribofuranosylhypoxanthine; 9-.beta.-D-Ribofuranosylhypoxanthine; NSC-20262; 9-beta-D-ribofuranosyl-9H-purin-6-ol; CID 5274258; SMR000058316; MFCD00066770; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-1H-purin-6-one; 1,9-Dihydro-9-beta-D-ribofuranosyl-6H-purin-6-one; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one; DTXCID0025993; .beta.-Inosine; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-hydroxypurin-9-yl)oxolane-3,4-diol; 9-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1H-purin-6(9H)-one; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6,9-dihydro-3H-purin-6-one; 9-[(2S,5S)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one; CAS-58-63-9; SR-01000721862; EINECS 200-390-4; Catacol; NSC20262; UNII-5A614L51CT; 3h-inosine; 2ada; 2fqw; .beta.-D-Ribofuranoside, hypoxanthine-9; NCGC00095787-01; Hypoxanthine, 9-.beta.-D-ribofuranosyl-; Inosine,(S); Inotin (TN); Inosine (JAN/INN); 1a4m; INOSINE [INCI]; Inosine (8CI,9CI); INOSINE [INN]; INOSINE [JAN]; INOSINE [MI]; INOSINE [MART.]; Opera_ID_1628; INOSINE [WHO-DD]; INOSINE [WHO-IP]; bmse000098; bmse000888; bmse000978; cid_6021; CHEMBL1556; SCHEMBL15804; KBioGR_002560; KBioSS_002569; INOSINE [USP IMPURITY]; GTPL4554; 9-b-D-Ribofuranosylhypoxanthine; Hypoxanthine-9-D-ribofuranoside; Inosine, >=99% (HPLC); 9beta-D-Ribofuranosylhypoxanthine; BDBM22104; KBio2_002560; KBio2_005128; KBio2_007696; KBio3_003038; 9-b-D-ribofuranosyl-Hypoxanthine; cMAP_000084; HMS2235I17; Hypoxanthine-9-delta-ribofuranoside; 9-beta-D-ribofuranosyl-Hypoxanthine; AMY30713; HY-N0092; ZINC8855117; 9beta-delta-Ribofuranosylhypoxanthine; Tox21_111522; BDBM50366815; beta-D-Ribofuranoside hypoxanthine-9; hypoxanthine-9 beta-D-Ribofuranoside; s2442; 9-beta-delta-Ribofuranosylhypoxanthine; AKOS015969695; AKOS015995607; AKOS024462561; Atorel; HXR; Hypoxanthine D-riboside; Tox21_111522_1; 9-beta-delta-ribofuranosyl-Hypoxanthine; AM83935; CCG-267127; CS-5845; DB04335; DIDANOSINE IMPURITY B [WHO-IP]; beta-delta-Ribofuranoside hypoxanthine-9; Hypoxanthine 9-beta-delta-ribofuranoside; hypoxanthine-9 beta-delta-Ribofuranoside; Hypoxanthine-9-beta-delta-ribofuranoside; SMP1_000165; NCGC00095787-05; NCGC00096119-02; NCGC00096119-03; AS-11754; BP-51105; 9-(beta-D-ribofuranosyl)-9H-purin-6-ol; ADENOSINE IMPURITY G [EP IMPURITY]; DB-029916; DIDANOSINE IMPURITY B [EP IMPURITY]; I0037; C00294; D00054; EN300-310328; 1,9-dihydro-9-b-D-ribofuranosyl-6H-Purin-6-one; Q422564; SR-01000721862-2; SR-01000721862-3; AC89F8E4-FD89-45EE-8B41-94DFC07AB42F; BRD-K79612754-001-21-7; 1,9-Dihydro-9-beta-delta-ribofuranosyl-6H-purin-6-one; 6H-Purin-6-one, 1,9-dihydro-9-beta-D-ribofuranosyl-; Z2681890654; 9-.BETA.-D-RIBOFURANOSYL-1,9-DIHYDRO-6H-PURIN-6-ONE; 9-beta-D-Ribofuranosyl-1,9-dihydro-6H-purin-6-one (Inosine); 9-.BETA.-D-RIBOFURANOSYL-1,9-DIHYDRO-6H-PURIN-6-ONE [WHO-IP]; (2R,3S,4R,5R)-2-(hydroxymethyl)-5-(6-hydroxy-9H-purin-9-yl)tetrahydrofuran-3,4-diol; 9-(3,4-DIHYDROXY-5-HYDROXYMETHYL-TETRAHYDRO-FURAN-2-YL)-1,9-DIHYDRO-PURIN-6-ONE; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-purin-6-one; 9-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3H-purin-6(9H)-one